<DOC>
	<DOCNO>NCT00003449</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness dexamethasone plus paclitaxel gemcitabine treat patient platinum-resistant recurrent ovarian cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , progression time , survival patient platinum-resistant ovarian cancer treat weekly paclitaxel gemcitabine . - Determine toxic effect regimen patient . - Evaluate toxic effect safety profile premedication steroid regimen patient . OUTLINE : Patients stratify accord prior treatment paclitaxel ( none relapse 6 month paclitaxel versus progressive disease relapse le 6 month paclitaxel ) . Patients receive dexamethasone IV , paclitaxel IV follow gemcitabine IV , 3 consecutive week day 1 , 8 , 15 . Treatment continue every 4 week absence disease progression unacceptable toxicity . All patient follow death . PROJECTED ACCRUAL : Approximately 18-35 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent ovarian epithelial cancer Platinum resistant disease define : Progression recent platinumbased chemotherapy OR Relapse le 6 month platinumbased chemotherapy Measurable evaluable disease Elevated CA125 allow Positive cytology eligible PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) AST le 3 time ULN Renal : Creatinine great 2 mg/dL Neurologic : No peripheral neuropathy great grade 2 Other : No serious medical illness psychiatric condition . PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent hematopoietic growth factor Chemotherapy : See Disease Characteristics No prior gemcitabine No prior paclitaxel administer weekly Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Recovered acute toxic effect secondary prior therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>